GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsCHMP positive opinion is based on a robustanalytical, non-clinical and clinical data package comparing Avzivi® to thereference product Avastin® Guangzhou, China– June 3, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative...
Guangzhou, China– June 2 , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosesesimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 study of BAT8006, afolate receptor α antibo...
Bio-Theraand STADA h ave reached an exclusive commercialization and license agreement forBAT2506, a biosesesimilar candidate to Simponi ® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhave exclusive rights to commercialize the product ...
